Figure 2.

Myosin Modulators

Omecamtiv was developed to improve contractile force for treatment of dilated cardiomyopathy. The mechanisms of this drug are complicated, but increased attachment time of myosin cross bridges to actin serves to activate the thin filament and increase contractility. Conversely, mavacamten and similar compounds were developed to decrease contractile force for treatment of hypertrophic cardiomyopathy. These compounds act by decreasing myosin ATPase activity, resulting in the formation of fewer myosin-actin cross bridges. Figure created with biorender.com.